Interstitial lung disease refers to a group of over 200 lung disorders that inflame or scar the tissues between the tiny air sacs (alveoli) in the lungs. Common symptoms include shortness of breath, dry cough, and fatigue. The leading cause isunknown, however certain drugs, environmental exposures, and connective tissue diseases may play a role. Diagnosis involves pulmonary function tests, chest imaging like HRCT scans, and occasionally lung biopsies. Treatment focuses on managing symptoms, slowing disease progression, and treating the underlying cause if identifiable.

Market key trends:

The Global Interstitial Lung Disease Market Size is expected to witness significant growth due to the rising geriatric population globally. As per the UN stats, people aged 60 or older numbered 962 million in 2017 and is expected to reach nearly 2.1 billion by 2050. This accelerating aging trend has direct implications on the prevalence of interstitial lung disease since it rises sharply with age and primarily affects people over 50 years of age. Additionally, improved awareness about this rare condition and availability of effective treatments will also aid the market growth over the coming years. Another major factor fueling the adoption includes growing pollution levels globally which is a prominent risk factor for various lung disorders.

Porter's Analysis

Threat of new entrants: Low capital requirements and lack of threat from patents allows new companies to easily enter the market. However, established brands and need for extensive R&D limits threats.

Bargaining power of buyers: Large customer base including hospitals and patients gives buyers significant bargaining power to negotiate on prices.

Bargaining power of suppliers: Few major players controlling key raw materials and patents results in higher bargaining power of suppliers. Supplier concentration keeps prices in check.

Threat of new substitutes: Limited availability of alternative treatment options reduces threat of substitutes. However, focus on developing new drugs remains high.

Competitive rivalry: Presence of many local and global brands leads to intense competition. companies respond with emphasis on branding, marketing and innovative drugs.

Read Our More Blogs : https://medicalinfoblogs.weebly.com/blog/interstitial-lung-disease-market-is-estimated-to-witness-high-growth-owing-to-increase-in-geriatric-population